Priorities for rapid and cost-effective vaccines to improve outbreak responses.
Gilbert SC., (2025), PLoS Biol, 23
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman N. et al, (2025), Lancet Microbe, 6
Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.
Vatzia E. et al, (2024), NPJ Vaccines, 9
Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine.
Wee EG-T. et al, (2024), Vaccines (Basel), 12
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Flaxman A. et al, (2024), PLoS Pathog, 20
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
Bissett C. et al, (2024), NPJ Vaccines, 9
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.
Drury RE. et al, (2024), Nat Commun, 15
Predicting airway immune responses and protection from immune parameters in blood following immunization in a pig influenza model.
Gubbins S. et al, (2024), Front Immunol, 15
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Port JR. et al, (2023), Nat Commun, 14
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D. et al, (2023), Lancet Infect Dis, 23, 956 - 964
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Kaplonek P. et al, (2023), Nat Immunol, 24, 1161 - 1172
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
Hotez PJ. et al, (2023), BMJ Glob Health, 8
Factors, enablers and challenges for COVID-19 vaccine development.
Excler J-L. et al, (2023), BMJ Glob Health, 8
Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
Privor-Dumm L. et al, (2023), BMJ Glob Health, 8
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Zhang P. et al, (2023)